T2 Biosystms Stock Today
| TTOO Stock | USD 0.57 0.07 14.00% |
Performance0 of 100
| Odds Of DistressOver 80
|
T2 Biosystms is selling at 0.57 as of the 30th of November 2024; that is 14.00 percent increase since the beginning of the trading day. The stock's open price was 0.5. T2 Biosystms has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for T2 Biosystms are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of June 2023 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of August 2014 | Category Healthcare | Classification Health Care |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 21.04 M outstanding shares of which 1.02 M shares are at this time shorted by private and institutional investors with about 1.26 trading days to cover. More on T2 Biosystms
Moving together with TTOO Stock
Moving against TTOO Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
TTOO Stock Highlights
| CEO President | BSc III | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Drugs (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Drugs, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsT2 Biosystms can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand T2 Biosystms' financial leverage. It provides some insight into what part of T2 Biosystms' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
T2 Biosystms (TTOO) is traded on NASDAQ Exchange in USA. It is located in 101 Hartwell Avenue, Lexington, MA, United States, 02421 and employs 113 people. T2 Biosystms is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.48 M. T2 Biosystms conducts business under Biotechnology sector and is part of Health Care industry. The entity has 21.04 M outstanding shares of which 1.02 M shares are at this time shorted by private and institutional investors with about 1.26 trading days to cover.
T2 Biosystms currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check T2 Biosystms Probability Of Bankruptcy
Ownership AllocationT2 Biosystms secures a total of 21.04 Million outstanding shares. The majority of T2 Biosystms outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to take positions in T2 Biosystms to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in T2 Biosystms. Please pay attention to any change in the institutional holdings of T2 Biosystms as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check TTOO Ownership Details
TTOO Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Cwm, Llc Duplicate | 2024-06-30 | 310 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 205 | |
| Bank Of America Corp | 2024-06-30 | 128 | |
| International Assets Investment Management, Llc | 2024-09-30 | 65.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 28.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 15.0 | |
| Jjj Advisors Inc | 2024-06-30 | 9.0 | |
| U.s. Bancorp | 2024-06-30 | 3.0 | |
| Ubs Group Ag | 2024-06-30 | 1.0 | |
| Armistice Capital, Llc | 2024-09-30 | 1.4 M | |
| Vanguard Group Inc | 2024-09-30 | 390.4 K |
T2 Biosystms Historical Income Statement
TTOO Stock Against Markets
T2 Biosystms Corporate Management
| Roger Smith | Senior Development | Profile | |
| Aparna MD | Chief Board | Profile | |
| Kelley Morgan | Chief Officer | Profile | |
| Michael Esq | Sr Counsel | Profile | |
| Brett Giffin | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.